PMC:7441788 / 19229-19720
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T110 | 307-309 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T103 | 269-277 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T183 | 50-52 | http://purl.obolibrary.org/obo/CLO_0001382 | denotes | 48 |
| T184 | 341-342 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T233 | 39-44 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T234 | 61-66 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T235 | 141-146 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T236 | 183-188 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T237 | 307-309 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T239 | 466-471 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T105 | 269-277 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T143 | 0-14 | Sentence | denotes | Yu et al [56]. |
| T144 | 15-189 | Sentence | denotes | Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. |
| T145 | 190-318 | Sentence | denotes | HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. |
| T146 | 319-409 | Sentence | denotes | Mortality was used as a measure of outcome and the study included critically ill patients. |
| T147 | 410-491 | Sentence | denotes | Retrospective design of the study and the number of HCQ group patients was small. |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 641 | 307-311 | Gene | denotes | IL-6 | Gene:3569 |
| 647 | 278-286 | Species | denotes | patients | Tax:9606 |
| 648 | 400-408 | Species | denotes | patients | Tax:9606 |
| 649 | 472-480 | Species | denotes | patients | Tax:9606 |
| 680 | 35-38 | Chemical | denotes | HCQ | MESH:D006886 |
| 681 | 57-60 | Chemical | denotes | HCQ | MESH:D006886 |
| 682 | 76-79 | Chemical | denotes | HCQ | MESH:D006886 |
| 683 | 137-140 | Chemical | denotes | HCQ | MESH:D006886 |
| 684 | 179-182 | Chemical | denotes | HCQ | MESH:D006886 |
| 685 | 190-193 | Chemical | denotes | HCQ | MESH:D006886 |
| 713 | 241-250 | Disease | denotes | mortality | MESH:D003643 |
| 714 | 254-268 | Disease | denotes | critically ill | MESH:D016638 |
| 715 | 269-277 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 716 | 319-328 | Disease | denotes | Mortality | MESH:D003643 |
| 717 | 385-399 | Disease | denotes | critically ill | MESH:D016638 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T1214 | 307-311 | Protein | denotes | IL-6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T109 | 307-309 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T96 | 269-277 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 641 | 307-311 | Gene | denotes | IL-6 | Gene:3569 |
| 647 | 278-286 | Species | denotes | patients | Tax:9606 |
| 648 | 400-408 | Species | denotes | patients | Tax:9606 |
| 649 | 472-480 | Species | denotes | patients | Tax:9606 |
| 680 | 35-38 | Chemical | denotes | HCQ | MESH:D006886 |
| 681 | 57-60 | Chemical | denotes | HCQ | MESH:D006886 |
| 682 | 76-79 | Chemical | denotes | HCQ | MESH:D006886 |
| 683 | 137-140 | Chemical | denotes | HCQ | MESH:D006886 |
| 684 | 179-182 | Chemical | denotes | HCQ | MESH:D006886 |
| 685 | 190-193 | Chemical | denotes | HCQ | MESH:D006886 |
| 713 | 241-250 | Disease | denotes | mortality | MESH:D003643 |
| 714 | 254-268 | Disease | denotes | critically ill | MESH:D016638 |
| 715 | 269-277 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 716 | 319-328 | Disease | denotes | Mortality | MESH:D003643 |
| 717 | 385-399 | Disease | denotes | critically ill | MESH:D016638 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T143 | 0-14 | Sentence | denotes | Yu et al [56]. |
| T144 | 15-189 | Sentence | denotes | Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group. |
| T145 | 190-318 | Sentence | denotes | HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level. |
| T146 | 319-409 | Sentence | denotes | Mortality was used as a measure of outcome and the study included critically ill patients. |
| T147 | 410-491 | Sentence | denotes | Retrospective design of the study and the number of HCQ group patients was small. |